All Health & Wellness stories, newest first.
The newest Lilly trial shows a drug that could change diabetes care. How it gets priced, marketed and bootlegged will decide whether that happens.
Retatrutide delivered an average of 70.3 lbs of weight loss over 80 weeks in Phase 3 trials. Novo Nordisk’s Wegovy pill has already logged 2 million prescriptions since January.
Unregulated peptides are exposing what happens when access outpaces oversight.
Kennedy is pushing changes the FDA has resisted for years. Whether that makes the market safer or just more official is the question the policy doesn’t answer.
